Journal of Pain & Palliative Care Pharmacotherapy最新文献_第6页

Review of Dopamine Antagonists for Nausea and Vomiting in Palliative Care Patients. 多巴胺拮抗剂治疗姑息治疗患者恶心呕吐的研究进展。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-03-01 Epub Date: 2023-10-16 DOI: 10.1080/15360288.2023.2268065

Grace Jenkins

{"title":"Review of Dopamine Antagonists for Nausea and Vomiting in Palliative Care Patients.","authors":"Grace Jenkins","doi":"10.1080/15360288.2023.2268065","DOIUrl":"10.1080/15360288.2023.2268065","url":null,"abstract":"Symptoms of nausea and vomiting are common in palliative care and hospice patients. One of the many classes of medications used for the treatment of nausea and vomiting is dopamine receptor antagonists which are particularly helpful for treating nausea mediated by the chemoreceptor trigger zone (CTZ) and impaired gastrointestinal function. While dopamine antagonists can be very effective treatments for nausea they should be used with caution as they carry the risk of QTc prolongation, have a FDA black box warning for tardive dyskinesia (TD), and increased risk of precipitating psychosis and death in patients with dementia. This review will cover haloperidol, olanzapine, prochlorperazine, and metoclopramide for treatment of nausea and vomiting including evidence of efficacy, pharmacokinetics, and pharmacodynamics to improve safe and effective utilization in clinical practice. This includes medication receptor site affinities at histaminic, muscarinic, serotonergic, and alpha-adrenergic receptors which can help providers anticipate potential adverse effects and risk of extrapyramidal symptoms (EPS), TD, and QTc prolongation. This review also includes considerations for dose adjustments based on renal function, hepatic function, and age. Understanding the pharmacology of dopamine antagonists can help providers choose the best treatment for control of nausea and vomiting and subsequently improve patients' quality of life.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"38-44"},"PeriodicalIF":1.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41236179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Year in Review: 2023. 一年回顾：2023.

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-03-01 Epub Date: 2024-02-12 DOI: 10.1080/15360288.2024.2313946

Laura Meyer-Junco

引用次数: 0

A Tool for Deprescribing Antithrombotic Medication in Palliative Cancer Patients: A Retrospective Evaluation. 癌症姑息治疗患者的抗血栓药物处方工具：回顾性评估

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-03-01 Epub Date: 2023-12-18 DOI: 10.1080/15360288.2023.2288093

Angela Riveras, Mirjam Crul, Jozien van der Kloes, Monique Steegers, Bregje Huisman

{"title":"A Tool for Deprescribing Antithrombotic Medication in Palliative Cancer Patients: A Retrospective Evaluation.","authors":"Angela Riveras, Mirjam Crul, Jozien van der Kloes, Monique Steegers, Bregje Huisman","doi":"10.1080/15360288.2023.2288093","DOIUrl":"10.1080/15360288.2023.2288093","url":null,"abstract":"Treating palliative cancer patients with antithrombotics is challenging because of the higher risk for both venous thromboembolism and major bleeding. There is a lack of available guidelines on deprescribing potentially inappropriate antithrombotics. We have therefore created an antithrombotics scheme to aid in (de)prescribing antithrombotics. A retrospective single-center clinical cohort observational study was performed to evaluate it. Patients with solid tumors with a life expectancy of less than 3 months seen by the palliative team were included. Comparisons were made between patients who were treated according to the antithrombotics scheme and those who were not. 47.6% of patients used antithrombotics. One hundred and eleven patients were included for analysis. Most patients used antithrombotics according to the scheme (n = 80, 72.1%). Eleven patients experienced a clinical event, seven patients in the scheme adherence group (9.9%) and four in the no scheme adherence group (13.8%), which was not statistically significant (p = 0.726). The higher frequency of clinical events in the group without scheme adherence suggests that (de)prescribing antithrombotics according to the antithrombotics scheme is safe. The results of this study suggest that the antithrombotics scheme could aid healthcare professionals identifying possible inappropriate antithrombotics in palliative cancer patients. Further prospective research is needed to investigate this tool.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"20-27"},"PeriodicalIF":1.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138805110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Fosaprepitant for Management of Suspected Antimicrobial-Associated Nausea: A Case Report. 使用磷沙匹坦治疗疑似抗菌素相关恶心:1例报告。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-03-01 Epub Date: 2023-11-20 DOI: 10.1080/15360288.2023.2282465

Brandon Perkovich, Rabia S Atayee, Jennifer S Kim, Tamara Rubenzik

{"title":"Use of Fosaprepitant for Management of Suspected Antimicrobial-Associated Nausea: A Case Report.","authors":"Brandon Perkovich, Rabia S Atayee, Jennifer S Kim, Tamara Rubenzik","doi":"10.1080/15360288.2023.2282465","DOIUrl":"10.1080/15360288.2023.2282465","url":null,"abstract":"Intractable nausea can occur in numerous settings. We report on a 49-year-old woman with a past medical history of cystic fibrosis (CF) with chronic hypoxia, chronic nausea, complex infection history and frequent hospitalizations who was admitted to an academic medical center with a CF exacerbation. Her chronic nausea worsened with the use of antimicrobials, and she was unable to tolerate dopamine or serotonin antagonist antiemetics. Nausea persisted despite the use of benzodiazepines and antihistamines. She was given a one-time dose of fosaprepitant 150 mg intravenously (IV) with marked improvement of her nausea. During subsequent exacerbations, she again developed severe nausea which continued to respond well to a one-time dose of fosaprepitant 150 mg IV. Fosaprepitant is a substance P/neurokinin-1 (NK1) receptor antagonist that is FDA-approved for the prevention of chemotherapy-induced nausea and vomiting and has been used to prevent post-operative nausea and vomiting. Its use in other contexts has not been well established. This case suggests a role for fosaprepitant in the management of nausea outside the context of chemotherapy or general anesthesia.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"28-32"},"PeriodicalIF":1.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138176477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Multicenter Retrospective Observational Study Analyzing the Effect of Polypharmacy on Oxycodone Tolerability. 一项多中心回顾性观察研究，分析多重用药对羟考酮耐受性的影响。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-16 DOI: 10.1080/15360288.2023.2301341

Katsuya Makihara, Yoshihiro Yamamoto, Masayuki Miyazaki, Maho Taguchi, Junya Sato, Hisamitsu Takase, Yasuhito Uezono

{"title":"A Multicenter Retrospective Observational Study Analyzing the Effect of Polypharmacy on Oxycodone Tolerability.","authors":"Katsuya Makihara, Yoshihiro Yamamoto, Masayuki Miyazaki, Maho Taguchi, Junya Sato, Hisamitsu Takase, Yasuhito Uezono","doi":"10.1080/15360288.2023.2301341","DOIUrl":"10.1080/15360288.2023.2301341","url":null,"abstract":"Polypharmacy is becoming increasingly troublesome in the treatment of cancer. The aim of this study was to explore the effects of concomitant polypharmacy comprising drugs that inhibit CYP3A4 and/or CYP2D6 on the oxycodone tolerability in patients with cancer. We conducted a multicenter retrospective study encompassing 20 hospitals. The data used for the study were obtained during the first 2 wk of oxycodone administration. The incidence of oxycodone discontinuation or dose reductions due to side effects and oxycodone-induced nausea and vomiting (OINV) were compared between patients not treated with either inhibitor and those treated with concomitant CYP3A4 or CYP2D6 inhibitors. The incidence of oxycodone discontinuation or dose reductions in patients treated with ≥3 concomitant CYP2D6 inhibitors (18.2%) tended to be higher than that in patients without this treatment (8.2%; p = 0.09). Moreover, the incidence of OINV in patients treated with 2 concomitant CYP3A4 inhibitors (29.8%) was significantly higher than that in patients without this treatment (15.5%; p = 0.049). Multivariate analysis showed that more than two concomitant CYP3A4 inhibitors and no concomitant use of naldemedine were independent risk factors for OINV. Concomitant polypharmacy involving CYP3A4 inhibitors increases the risk of OINV. Therefore, medications concomitantly used with oxycodone should be optimized.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"3-12"},"PeriodicalIF":1.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polypharmacy and Reversible Drug Induced QT Prolongation in a Patient with Advanced Cancer: Case Report. 一名晚期癌症患者的多重用药和可逆药物诱发的 QT 间期延长：病例报告。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-05 DOI: 10.1080/15360288.2023.2297218

Gabriela Cerdà, Joaquim Julià-Torras, Jesús González-Barboteo, Margarita Romeo, Agnès Calsina-Berna

引用次数: 0

"I Just Don't Feel Heard": A Case Study on Opioid Use Disorder and Pain Management. “我只是不觉得被听到”:阿片类药物使用障碍和疼痛管理的案例研究。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-08-28 DOI: 10.1080/15360288.2023.2250340

Aila Malik, Peter D Vu, A Sarah Cohen, Vishal Bansal, Morgan R Cowan, Gregory M Blazek, Tiffany Champagne-Langabeer

引用次数: 0

Mpox Pain Management with Topical Agents: A Case Series. m痘疼痛管理与局部药物:一个案例系列。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-08-31 DOI: 10.1080/15360288.2023.2250762

Mariam Shabbir, Maria Lorraine Bugayong, Michael Anthony DeVita

引用次数: 0

Oxygen Therapy in the Last Days and Hours of Life: From Evidence to Practice. 氧气疗法在生命的最后几天和几个小时:从证据到实践。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-09-07 DOI: 10.1080/15360288.2023.2250332

Mónica Carqueijó

引用次数: 0

Using Interdisciplinary Teams to Mitigate the Effects of Drug Shortages in Palliative Care: The Case of Lorazepam Injection. 使用跨学科团队减轻姑息治疗中药物短缺的影响：以洛拉西泮注射液为例。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-11-28 DOI: 10.1080/15360288.2023.2269899

Natalie Hartung, Zainab Fatima, Danielle M Noreika, J Brian Cassel, Katie S Adams

{"title":"Using Interdisciplinary Teams to Mitigate the Effects of Drug Shortages in Palliative Care: The Case of Lorazepam Injection.","authors":"Natalie Hartung, Zainab Fatima, Danielle M Noreika, J Brian Cassel, Katie S Adams","doi":"10.1080/15360288.2023.2269899","DOIUrl":"10.1080/15360288.2023.2269899","url":null,"abstract":"Given the rising frequency of drug shortages in hospitals, interdisciplinary collaboration is necessary to manage medications, modify electronic medical records, and evaluate safety outcomes. One such shortage impacted lorazepam injection, a medication commonly used in palliative care to treat anxiety, agitation, and seizures. In anticipation of the lorazepam shortage in the summer of 2022, pharmacy staff collaborated with palliative care physicians to identify alternative treatment recommendations when providers were prohibited from ordering lorazepam injection. Before the shortage, lorazepam was used an average of 95 times per month on the palliative care unit. The overall use of benzodiazepines decreased substantially following the recommendation for the therapeutic alternative, midazolam, during the shortage. Once the shortage ended, use roughly returned to pre-shortage baselines. During this time, there were no patient safety events documented on the palliative care unit. Moreover, no changes to the care experience were reported by patients, family/caregivers, providers, or staff. The collaborative effort between pharmacy and palliative care specialists resulted in alternative treatments for palliative care patients during the drug shortage. This preserved the hospital's supply of lorazepam injection for a patient population with no suitable alternatives while still allowing for management of palliative patients.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"336-341"},"PeriodicalIF":1.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49691008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0